Novo Nordisk yesterday announced amazing Q1 results, which have caused its shares to rise over 4% (Copenhagen). Both the Danish group’s revenues and its net profit increased–respectively by 5% and 6% at Constant Exchange Rate, thus its management has improved the current year guidances. Outstanding sales were yielded from diabetes products, contrarily to the trend observed for insulins manufactured by other producers such as Sanofi and Eli Lilly. The basal insulin Tresiba has delivered record sales, with a 18% increase (DKK1,8bn), as well as the obesity drug Saxenda (+43%) and the diabetes drug Victoza (+4%). Good news from the recently-created Haemophilia division (+7%) and Novoseven.